Significance of combined detection of serum HMGB1 and prostate-specific antigen in predicting the recurrence of local prostate cancer
-
摘要:
目的 探讨局限性前列腺癌经前列腺癌氩氦冷冻治疗后血清HMGB1和PSA表达在预测治疗后复发中的临床价值。 方法 应用酶联免疫吸附试验(ELISA) 测定80例局限性前列腺癌患者(Pca组) 冷冻治疗前、后和30例前列腺良性增生患者(BPH组)、20例健康对照者血清HMGB1和PSA表达。Pca组术后PSA、MRI随访, 经病理穿刺活检证实: 局部复发9例, 远处转移3例。比较Pca组术后血清HMGB1表达, 及预测前列腺癌复发的价值。 结果 Pca组术前血清HMGB1 (94.0±77.4 ng/mL) 相比BPH组(33.2±7.4 ng/mL) 和健康对照组(24.7±7.3 ng/mL) 显著升高(P < 0.001)。Pca组术后血清HMGB1 (55.0±11.0 ng/mL) 较术前显著降低(P=0.005);Pca组冷冻治疗后, 复发者术后HMGB1平均值为(70.8±2.7) ng/mL, 无复发者术后HMGB1平均值为(55.0±10.8) ng/mL, 差异有统计学意义(P=0.001);3例远处转移患者血清HMGB1水平较9例局部复发者显著升高(94.2±17.9 vs.73.1±7.9ng/mL)。术后血清HMGB1相比PSA预测复发性Pca的敏感性高(83.3%Vs.66.7%), 而两者联合诊断的特异性较单一PSA高(95.6%vs.82.4%)。Pca组术后HMGB1表达与临床分期、复发和转移(P < 0.001) 相关, 与Gleason评分无显著相关性(P > 0.05)。 结论 血清HMGB1在Pca中高表达, 提示血清HMGB1可作为一项预测和预后指标。此外, Pca患者冷冻治疗后联合检测HMGB1和PSA对于复发患者可提高早期诊断率, 有效的指导病理穿刺活检及后续治疗。 Abstract:Objective This study aimed to investigate the expression of serum HMGB1 and prostate-specific antigen (PSA) in diagnosing the recurrence of localized prostate cancer (Pca) in patients who had undergone cryotherapy treatment. Methods Enzyme-linked immunosorbent assay (ELISA) was performed to measure the serum HMGB1 levels of 80 prostate cancer patients pre-and post-operation, as well as the PSA levels in 30 benign prostatic hyperplasia (BPH) and 20 healthy subjects.During follow-up, PSA analysis, MRI, and pathology biopsy confirmed nine cases of local recurrence and three cases of metastasis.The post-operative serum HMGB1 expression and its diagnosis value in Pca recurrence were also determined. Results First, the HMGB1expression level in Pca (94.0 ± 77.4 ng/mL) was significantly higher than those in BPH (33.2 ± 7.4 ng/mL) and healthy (24.7 ± 7.3 ng/mL) subjects (P < 0.001).Second, post-operative serum HMGB1 was 55.03 ± 11.00 ng/mL, which significantly differed from the pre-operative level (P = 0.005).Post-operative serum HMGB1 in the recurrence group significantly different from that in the recurrence-free group (70.8 ± 2.7 vs.55.0 ± 10.8 ng/mL).Serum HMGB1 in the three metastatic cases were significantly higher than in the nine cases of local recurrence (94.2 ± 17.9 vs.73.1 ± 7.9 ng/mL).The single diagnostic value of serum HMGB1 was more sensitive than PSA in predicting the recurrence of Pca after local treatment (83.3% vs.66.7%), and the overall diagnostic specificity was higher than that of PSA alone (95.6% vs.82.4%).Third, serum HMGB1 in Pca patients after cryotherapy was related to the clinical stage and recurrence (P < 0.001), but was not correlated with the Gleason score. Conclusion Our findings indicated that serum HMGB1 levels were higher in Pca subjects, suggesting that serum HMGB1 can be used as a predictive and prognostic factor.Moreover, co-detection of serum HMGB1 andPSA can improve the early diagnosis of Pca recurrence after cryotherapy. -
Key words:
- HMGB1 /
- prostate cancer /
- tumor marker /
- recurrence /
- prognosis
-
表 1 血清HMGB1和PSA的表达（x±s）
Table 1. The expression of HMGB1 and PSA among the groups
表 2 血清HMGB1、PSA预测复发性Pca（x±s）
Table 2. Serum HMGB1 and PSA in predicting recurrence of Pca
表 3 Pca组患者术后血清HMGB1与临床病理特征
Table 3. Clinicopathologic features of Pca patients based on post-opera- tive serum HMGB1 levels
-
[1] Tanaka N, Fujimoto K, Hirayama, et al. Trends of the primary therapyfor patients with prostate cancer in Nara uro-oncological researchgroup (NUORG): a comparison between the CaPSURE data and theNUORG data[J]. Jpn J Clin Onco, 2010, 40 (6): 588-592. doi: 10.1093/jjco/hyq008 [2] Cohen JK, Miller RJ Jr, Ahmed S, et al. Ten-year biochemical dis ease control for patients with prostate cancer treated with cryosur gery as primary therapy[J]. Urology, 2008;71 (3): 515-518. [3] 郭志. 关注冷冻消融治疗前列腺癌的若干问题[J]. 中华医学杂志, 2010, 90 (42): 2959-2961. doi: 10.3760/cma.j.issn.0376-2491.2010.42.004 [4] 郭志, 王海涛, 邢文阁, 等. 冷冻消融治疗T3N0M0期前列腺癌的初步临床观察[J]. 中华医学杂志, 2010, 90 (40): 2815-2819. doi: 10.3760/cma.j.issn.0376-2491.2010.40.003 [5] Ishiguro H, Nakaigawa N, Miyoshi Y, et al. Receptor for advancedglycation end products (RAGE) and its ligand, amphoterin are over expressed and associated with prostate cancer development[J]. Pros tate, 2005, 64: 92-100. [6] Delong ER, DeLong DM, Clarke-Pearson DL. Comparing the ar eas under two or more correlated receiver operating characteristiccurves: a nonparametric approach[J]. Biometrics, 1988, 44 (3): 837-845. doi: 10.2307/2531595 [7] Kuniyasu H, Chihara Y, Kondo H, et al. Amphoterin induction inprostatic stromal cells by androgen deprivation is associated withmetastatic prostate cancer[J]. Oncol Rep, 2003, 10 (6): 1863-1868. [8] Akaike H, Kono K, Sugai H, et al. Expression of high mobilitygroup box chromosomal protein-1 (HMGB-1) in gastric cancer[J]. Anticancer Res, 2007, 27: 449-457. [9] Chung HW, Lee SG, Kim H, et al. Serum high mobility groupbox-1 (HMGB1) is closely associated with the clinical and patholog ic features of gastric cancer[J]. Transl Med, 2009, 7: 38. doi: 10.1186/1479-5876-7-38 [10] Lee H, Song M, Shin N, et al. Diagnostic significance of serumHMGB1 in colorectal carcinomas[J]. PLoS One, 2012, 7 (4): e34318. doi: 10.1371/journal.pone.0034318 [11] Brezniceanu ML, V lp K, B sser S, et al. HMGB1 inhibits celldeath in yeast and mammalian cells and is abundantly expressed inhuman breast carcinoma[J]. FASEB J, 2003, 17 (10): 1295-1297. doi: 10.1096/fj.02-0621fje [12] Sheng X, Du X, Zhang X, et al. Clinical value of serum HMGB1levels in early detection of recurrent squamous cell carcinoma ofuterine cervix: comparison with serum SCCA, CYFRA21-1, andCEA levels[J]. Croat Med J, 2009, 50 (5): 455-464. doi: 10.3325/cmj.2009.50.455 [13] Chen J, Liu X, Zhang J, et al. Targeting HMGB1 inhibits ovariancancer growth and metastasis by lentivirus-mediated RNA interfer ence[J]. J Cell Physio, 2012, 227 (11): 3629-3638. doi: 10.1002/jcp.24069 [14] Li T, Gui Y, Yuan T, et al. Overexpression of high mobility groupbox 1 with poor prognosis in patients after radical prostatectomy[J]. BJU Int, 2012, 110 (11 Pt C): E1125-E1130. [15] Kuban DA, Levy LB, Potters L, et al. Comparison of biochemicalfailure definitions for permanent prostate brachytherapy[J]. Int J Ra diat Oncol Biol Phys, 2006, 65 (5): 1487-1493. doi: 10.1016/j.ijrobp.2006.03.027 -
点击查看大图
表(3)
计量
- 文章访问数: 40
- HTML全文浏览量: 15
- PDF下载量: 1
- 被引次数: 0
下载:
